This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit <a href="https://ddjournalclub.substack.com?utm_medium=podcast&#38;utm_campaign=CTA_1">ddjournalclub.substack.com</a>

Drug Developers' Journal Club

TLRs as targets in SLE- Latest news

A quick summary for those who are not familiar with the phenomenon of primary failures. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit <a href="https://ddjournalclub.substack.com?utm_medium=podcast&#38;utm_campaign=CTA_1">ddjournalclub.substack.com</a>

Primary Anti-TNF failure

Enjoy This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit <a href="https://ddjournalclub.substack.com?utm_medium=podcast&#38;utm_campaign=CTA_1">ddjournalclub.substack.com</a>

Vitiligo Skin T Cells Are Prone to Produce Type 1 and Type 2 Cytokines to Induce Melanocyte Dysfunction and Epidermal Inflammatory Response Through Jak Signaling

Life Sciences

News

Science

Tech News

Important recent publications that is of interest to drug developers in all therapeutic areas <a href="https://ddjournalclub.substack.com?utm_medium=podcast">ddjournalclub.substack.com</a>

Drug Developers' Journal Club

Eswar Krishnan, MD

3 Episodes

TLRs as targets in SLE- Latest news

Primary Anti-TNF failure

Vitiligo Skin T Cells Are Prone to Produce Type 1 and Type 2 Cytokines to Induce Melanocyte Dysfunction and Epidermal Inflammatory Response Through Jak Signaling